Patents by Inventor Marc Labelle

Marc Labelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9611220
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: April 4, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • Patent number: 9611219
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: April 4, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • Publication number: 20160237037
    Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Type: Application
    Filed: February 26, 2014
    Publication date: August 18, 2016
    Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
  • Publication number: 20160102096
    Abstract: The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), and (IIIg). Compounds of Formula (I) have the structure: wherein Q, R1, R18, R19, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.
    Type: Application
    Filed: August 26, 2015
    Publication date: April 14, 2016
    Inventors: Thomas Boesen, Marc Labelle, Ying Yang, Neerja Saraswat, Dastagiri Dudekula, Cyril John Cook, Ramkrishna Reddy Vakiti, Rui Zhang, Farman Ullah
  • Patent number: 9221801
    Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Type: Grant
    Filed: August 28, 2014
    Date of Patent: December 29, 2015
    Assignee: Epitherapeutics APS
    Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
  • Publication number: 20150203453
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Application
    Filed: October 1, 2013
    Publication date: July 23, 2015
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • Publication number: 20140371195
    Abstract: The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Inventors: Marc Labelle, Thomas Boesen, Mukund Mehrotra, Qasim Khan, Farman Ullah
  • Publication number: 20140371214
    Abstract: Compounds of the form In which Q is selected from —CH?NR12, —W, —CH2NHR13, —CH?O and —CH(OR17)2 capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.
    Type: Application
    Filed: August 28, 2014
    Publication date: December 18, 2014
    Inventors: Marc Labelle, Thomas Boesen, Qasim Khan, Ramkrishna Reddy Vakiti, Utpal Sharma, Ying Yang, Mukund Mehrotra, Neerja Saraswat, Farman Ullah
  • Publication number: 20130273024
    Abstract: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.
    Type: Application
    Filed: March 26, 2013
    Publication date: October 17, 2013
    Inventors: Frank KAYSER, Marc Labelle, Bei Shan, Jian Zhang, Mingyue Zhou
  • Patent number: 8426358
    Abstract: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: April 23, 2013
    Assignee: Amgen Inc.
    Inventors: Frank Kayser, Marc Labelle, Bei Shan, Jian Zhang, Mingyue Zhou
  • Publication number: 20110206652
    Abstract: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.
    Type: Application
    Filed: April 14, 2011
    Publication date: August 25, 2011
    Applicant: Amgen Inc.
    Inventors: Frank Kayser, Marc Labelle, Bei Shan, Jian Zhang, Mingyue Zhou
  • Patent number: 7754890
    Abstract: Aryl sulfone compounds of formula I and II are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: July 13, 2010
    Assignee: Amgen Inc.
    Inventors: Pingchen Fan, Hiroyuki Goto, Xiao He, Makoto Kakutani, Marc Labelle, Dustin L. McMinn, Jay P. Powers, Yosup Rew, Daqing Sun, Xuelei Yan
  • Patent number: 7635695
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: December 22, 2009
    Assignee: Amgen Inc.
    Inventors: Simon A. Burkitt, Mario G. Cardozo, Timothy D. Cushing, Michael R. DeGraffenreid, Christopher N. Farthing, Xiaolin Hao, Juan C. Jaen, Xian Yun Jiao, David J. Kopecky, Marc Labelle, Sarah E. Lively, Dustin L. McMinn, Sven P. Rasmussen, Youngsook Shin, Marie-Louise Smith, Andrew Smith
  • Publication number: 20080269283
    Abstract: Aryl sulfone compounds of formula I and II are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:
    Type: Application
    Filed: June 27, 2008
    Publication date: October 30, 2008
    Inventors: Pingchen Fan, Hiroyuki Goto, Xiao He, Makoto Kukutani, Marc Labelle, Dustin L. McMinn, Jay P. Powers, Yosup Rew, Daqing Sun, Xuelei Yan
  • Patent number: 7402704
    Abstract: Aryl sulfone compounds of formula I and II are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: July 22, 2008
    Assignee: Amgen Inc.
    Inventors: Pingchen Fan, Hiroyuki Goto, Xiao He, Makoto Kakutani, Marc Labelle, Dustin L. McMinn, Jay P. Powers, Yosup Rew, Daqing Sun, Xuelei Yan
  • Publication number: 20080096900
    Abstract: The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.
    Type: Application
    Filed: June 26, 2007
    Publication date: April 24, 2008
    Applicant: Amgen Inc.
    Inventors: Frank Kayser, Marc LaBelle, Bei Shan, Jian Zhang, Mingyue Zhou
  • Publication number: 20070244096
    Abstract: Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
    Type: Application
    Filed: May 2, 2007
    Publication date: October 18, 2007
    Applicant: Japan Tobacco Inc.
    Inventors: Brian Fox, Noboru Furukawa, Xiaolin Hao, Kiyosei Iio, Takashi Inaba, Simon Jackson, Frank Kayser, Marc Labelle, Kexue Li, Takuya Matsui, Dustin McMinn, Nobuya Ogawa, Steven Rubenstein, Shoichi Sagawa, Kazuyuki Sugimoto, Masahiro Suzuki, Masahiro Tanaka, Guosen Ye, Atsuhito Yoshida, Jian Zhang
  • Patent number: 7244727
    Abstract: Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: July 17, 2007
    Assignee: Japan Tobacco Inc.
    Inventors: Brian M. Fox, Noboru Furukawa, Xiaolin Hao, Kiyosei Iio, Takashi Inaba, Simon M. Jackson, Frank Kayser, Marc Labelle, Kexue Li, Takuya Matsui, Dustin L. McMinn, Nobuya Ogawa, Steven M. Rubenstein, Shoichi Sagawa, Kazuyuki Sugimoto, Masahiro Suzuki, Masahiro Tanaka, Guosen Ye, Atsuhito Yoshida, Jian Zhang
  • Publication number: 20070155777
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.
    Type: Application
    Filed: February 21, 2007
    Publication date: July 5, 2007
    Applicants: Tularik Inc.
    Inventors: Simon Burkitt, Mario Cardozo, Timothy Cushing, Michael DeGraffeneid, Christopher Farthing, Xiaolin Hao, Juan Jaen, Xian Jiao, David Kopecky, Marc Labelle, Sarah Lively, Dustin McMinn, Sven Rasmussen, Youngsook Shin, Andrew Smith, Marie-Louise Smith
  • Publication number: 20070135464
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism and cell proliferation. The subject compounds contain fused carbocyclic or heterocyclic rings.
    Type: Application
    Filed: January 5, 2007
    Publication date: June 14, 2007
    Inventors: Michelle Browner, David Clark, Timothy Cushing, Xiaolin Hao, Ronald Hawley, Xiao He, Juan Jaen, Sharada Labadie, Marie-Louise Smith, Francisco Talamas, Nigel Walker, Marc Labelle